OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1
P. Rutgeerts, WJ Sandborn(Mayo Clinic in Arizona), Séverine Vermeire(KU Leuven), Yinghua Lang, Stephan R. Targan(Cedars-Sinai Medical Center), Edward V. Loftus(Mayo Clinic), Shin‐Da Lee(China Medical University), Pierre Desreumaux(Active Biotech (Sweden)), L-L Gao(Janssen (United States)), J F Colombel(European CanCer Organisation), Subrata Ghosh(University College Cork), Mikhail Blank(Janssen (Belgium)), S. B. Hanauer(University of Chicago), W de Villiers(University of Cape Town), B. Feagan, Christopher Gasink(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k